Publications by authors named "Hector Miguel Marcos-Prieto"
Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists.
Clin Gastroenterol Hepatol
March 2022
Background & Aims: Few prospective studies have assessed the safety of direct oral anticoagulants (DOACs) in elective endoscopy. Our primary aim was to compare the risks of endoscopy-related gastrointestinal bleeding and thromboembolic events in patients on DOACs or vitamin K antagonists (VKAs) in this setting. Secondarily, we examined the impact of the timing of anticoagulant resumption on the risk of delayed bleeding in high-risk therapeutic procedures.
View Article and Find Full Text PDFBackground & Aims: Management of delayed (within 30 days) postpolypectomy bleeding (DPPB) has not been standardized. Patients often undergo colonoscopies that do not provide any benefit. We aimed to identify factors associated with therapeutic intervention and active bleeding after DPPB.
View Article and Find Full Text PDFIntroduction: In Europe, gastric adenocarcinoma (GADC) is commonly regarded as a disease of the elderly. This study aims to assess the proportion, characteristics, and survival of patients diagnosed with GADC under the age of 60.
Materials And Methods: This is a retrospective, multicentric, and analytical study conducted at four tertiary Spanish hospitals.
Article Synopsis
- The study found that missed oesophageal cancer (MEC) occurs in 6.4% of diagnosed cases, highlighting a need for improved detection methods.
- MEC is more likely to be smaller and less frequently metastasized at diagnosis compared to other types of oesophageal cancer (non-MEC).
- The research indicates that the overall survival rates for MEC and non-MEC patients after two years are similar, emphasizing the need for better endoscopy practices to improve outcomes.
Background: Missed gastric cancer (MGC) is poorly documented in Mediterranean populations.
Aims: (1) To assess the rate, predictors and survival of MGC. (2) To compare MGC and non-MGC tumors.
Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study.
Helicobacter
October 2017
Background: Helicobacter pylori antibiotic resistance is an increasing problem worldwide. Pylera may be an option as salvage therapy.
Aim: To assess the effectiveness, safety, and tolerance of Pylera as a third-line in clinical practice.